Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis -: Results from the Dallas Heart Study

被引:86
作者
de Lemos, JA
Zirlik, A
Schönbeck, U
Varo, N
Murphy, SA
Khera, A
McGuire, DK
Stanek, G
Lo, HS
Nuzzo, R
Morrow, DA
Peshock, R
Libby, P
机构
[1] Univ Texas, SW Med Ctr, Div Cardiol, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA
[2] Brigham & Womens Hosp, Donald W Reynolds Cardiovasc Clin Res Ctr, Boston, MA 02115 USA
关键词
sCD40; ligand; CD40; atherosclerosis; diabetes; cholesterol;
D O I
10.1161/01.ATV.0000182904.08513.60
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives - The purpose of this study was to evaluate the associations between plasma levels of soluble CD40 ligand (sCD40L), atherosclerosis risk factors, and evidence of subclinical atherosclerosis. Methods and Results - Plasma levels of sCD40L were measured in 2811 subjects from the Dallas Heart Study, a multiethnic population-based cross-sectional study. Electron Beam Computed Tomography measurements of coronary artery calcium (CAC) and MRI measurements of aortic plaque were performed in 2198 and 1965 subjects, respectively. No association was observed between quartiles of sCD40L and age, sex, race, body mass index, diabetes, smoking, creatinine clearance, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or C-reactive protein. In contrast, weak but statistically significant associations were observed between sCD40L and total cholesterol and triglycerides. The prevalence of detectable CAC ( CAC score >= 10) and aortic plaque did not differ across sCD40L quartiles, and individuals with CAC scores < 10, >= 10 to 100, > 100 to 400, and > 400 had similar sCD40L levels. Conclusions - In a large and representative multiethnic population-based sample, sCD40L was not associated with most atherosclerotic risk factors or with subclinical atherosclerosis. These findings suggest that sCD40L will not be useful as a tool to screen for the presence of subclinical atherosclerosis in the population. Further evaluation of this biomarker should focus on settings in which platelet activation is common, such as following acute coronary syndromes or coronary revascularization procedures.
引用
收藏
页码:2192 / 2196
页数:5
相关论文
共 38 条
[1]   QUANTIFICATION OF CORONARY-ARTERY CALCIUM USING ULTRAFAST COMPUTED-TOMOGRAPHY [J].
AGATSTON, AS ;
JANOWITZ, WR ;
HILDNER, FJ ;
ZUSMER, NR ;
VIAMONTE, M ;
DETRANO, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (04) :827-832
[2]   Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk [J].
Ahn, ER ;
Lander, G ;
Jy, W ;
Bidot, CJ ;
Jimenez, JJ ;
Horstman, LL ;
Ahn, YS .
THROMBOSIS RESEARCH, 2004, 114 (02) :143-148
[3]   Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina -: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].
Aukrust, P ;
Müller, F ;
Ueland, T ;
Berget, T ;
Aaser, E ;
Brunsvig, A ;
Solum, NO ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
CIRCULATION, 1999, 100 (06) :614-620
[4]   Should soluble CD40 ligand be measured from serum or plasma samples? [J].
Bereczki, D ;
Nagy, E ;
Pál, A ;
Magyar, MT ;
Balla, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (06) :1129-1130
[5]  
BERECZKI D, 2003, ARTERIOSCLER THROMB, V23, P1130
[6]   Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma -: An in vivo study with high-resolution MRI [J].
Blake, GJ ;
Ostfeld, RJ ;
Yucel, EK ;
Varo, N ;
Schönbeck, U ;
Blake, MA ;
Gerhard, M ;
Ridker, PM ;
Libby, P ;
Lee, RT .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :E11-E14
[7]  
Cefalu W T, 1999, Diabetes Technol Ther, V1, P435, DOI 10.1089/152091599316964
[8]   Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy [J].
Cipollone, F ;
Mezzetti, A ;
Porreca, E ;
Di Febbo, C ;
Nutini, M ;
Fazia, M ;
Falco, A ;
Cuccurullo, F ;
Davì, G .
CIRCULATION, 2002, 106 (04) :399-402
[9]   Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis [J].
Deo, R ;
Khera, A ;
McGuire, DK ;
Murphy, SA ;
Neto, JDPM ;
Morrow, DA ;
de Lemos, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) :1812-1818
[10]   Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L [J].
Fan, Y ;
Ge, Y ;
Zhu, H ;
Wang, Y ;
Yang, B ;
Zhuang, Y ;
Ma, H ;
Zhang, X .
TISSUE ANTIGENS, 2004, 64 (03) :257-263